Allegaert K, Rayyan M, Cossey V, Van Geet C. Subcutaneous palivizumab (Synagis®) administration in an infant with congenital type 2B von Willebrand disease. J Pediatr Neonat Individual Med [Internet]. 2015Jan.27 [cited 2024Jul.17];4(1):e040104. Available from: https://jpnim.com/index.php/jpnim/article/view/040104